GlassScriptPhysician profile
Haley E Swanson
NPI 1972254118
$4,298.75
in general payments reported to CMS, 2019-2025
26 companies · $1,049 in 2025
The $1,049 reported for 2025 was more than what 88% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $587 · 2023: $1,390 · 2024: $1,272 · 2025: $1,049.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,586 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,586.36 |
| Education | $124.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $748.37 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $742.58 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $731.27 | 2022-2025 | |
| Pfizer INC. | $398.67 | 2022-2025 | |
| Lilly USA, LLC | $359.16 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $303.46 | 2022-2025 | Rexulti, Abilify Maintena |
| Astellas Pharma US INC | $203.21 | 2022-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $175.83 | 2023-2025 | Trelegy Ellipta, Shingrix |
| Currax Pharmaceuticals LLC | $98.04 | 2023-2024 | Contrave, Nexletol |
| Biohaven Pharmaceutical Holding Company LTD. | $65.48 | 2022 | |
| Lundbeck LLC | $52.53 | 2025 | Rexulti |
| Medicomp INC | $50.58 | 2023 | Telepatch Cardiac Monitor |
| Sumitomo Pharma America, INC. | $48.64 | 2025 | Gemtesa |
| Abbott Laboratories | $42.62 | 2025 | Freestyle Libre 3 |
| Exact Sciences Corporation | $38.93 | 2025 | Cologuard Collection Kit |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.85 | 2025 | Jardiance |
| Dexcom, INC. | $31.79 | 2024-2025 | Dexcom G6 Transmitter |
| Eisai INC. | $26.12 | 2024 | |
| Novartis Pharmaceuticals Corporation | $24.76 | 2022 | |
| Axsome Therapeutics, INC. | $21.73 | 2025 | Auvelity |
| Corcept Therapeutics | $19.67 | 2025 | Korlym |
| Boston Scientific Corporation | $17.47 | 2023 | |
| Mylan Specialty L.P. | $17.13 | 2024 | Yupelri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.41 | 2024 | Caplyta |
| Almatica Pharma LLC | $13.78 | 2022 | |
| Amgen INC. | $13.67 | 2025 | Repatha, Otezla |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Haley Swanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.